Pipeline

Disease Preclinical IND-Enabling Clinical Regulatory Status
End-Stage Liver Disease
51%
  Potential FastTrack and/or RMAT  
     
Inborn Errors of Metabolism (IEM's)
A1AT
51%
  Potential FastTrack and/or RMAT Orphan Designation
OTC Deficiency
30%
 
Disease Phase Clinical/Regulatory Status
End-Stage Liver Disease Preclinical Potential FastTrack and/or RMAT
Inborn Errors of Metabolism (IEM's)
A1AT Preclinical Potential FastTrack and/or RMAT
Orphan Designation
OTC Definciency Preclinical Potential FastTrack and/or RMAT

 

NovoTissues®

We believe that our proprietary 3D bioprinting platform enables us to deliver functional human tissues to treat several target diseases where there are significant unmet needs. We hope to serve as a ‘bridge to transplant’ for patients with limited treatment options by constructing surgically implantable tissues that restore significant function to a damaged tissue or organ.  Our ultimate goal is to delay or reduce the overall need for transplant.  Our future tissue products may include bioprinted tissues (patches, tubes, etc.) or hybrids comprised of bioprinted tissues and device components. 

Therapeutic-NovoTissue
NovoTissue® 1×1
Therapeutic-NovoTissue-5x5
NovoTissue® 5×5

We may also develop specific tissue targets with partners through technology licenses and royalty-bearing agreements, or may self-fund the development of our tissue targets through preclinical and clinical development.

During the past several years, we have implanted our 3D bioprinted human liver tissue patches onto the livers of diseased mice, and through serum and histopathologic evaluation of the implanted therapeutic tissue, showed engraftment, retention, and the potential for disease modification in two different disease models.  Our results have demonstrated a sustained presence of key human liver proteins and enzymes in the animal bloodstream.  In addition, our pathologic evaluation of diseased animals receiving our implanted bioprinted liver tissues in an Alpha-1-antitrypsin deficiency (A1AT) study suggested an approximately 75 percent reduction in the pathologic hallmarks of the disease in treated animals versus non-treated animals in the region of implant.